According to data compiled by Bloomberg, around 16.6 million shares of Biocon changed hands on the BSE in a single pre-market ...

Active Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share.

Active Pine is likely to sell up to 1.66 crore Biocon shares, equivalent to 1% equity, through a block deal worth ₹638.4 ...

True North is expected to be the seller in the transaction. The investment firm holds its Biocon stake through Activ Pine LLP ...

Biocon expects its biosimilars business to maintain double-digit revenue growth as it expands its portfolio, with management ...

Pertuzumab is an antibody used to treat HER2-positive breast cancer and is currently not manufactured locally in Brazil.

The block deal comes against the backdrop of Biocon's efforts to scale its biosimilars business, which the company expects ...

ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring additional 74.03 lakh shares for Rs 285.02 crore. It was ...

Biocon shares surged nearly 3% on Wednesday following a ₹635 crore block deal, where 1% equity changed hands at ₹385 per ...

Indian biopharma firm Biocon has announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab ...

Shreehas Tambe, CEO & Managing Director, BIOCON, said, "This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2 ...

Biocon has signed a 10-year contract with Bahiafarma and Bionovis to exclusively supply Pertuzumab, a HER2-positive breast cancer therapy, to Brazil's public healthcare sector.